186
Participants
Start Date
May 8, 2023
Primary Completion Date
July 1, 2027
Study Completion Date
January 1, 2028
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
Given SC
Biopsy Procedure
Undergo biopsy
Biospecimen Collection
Undergo blood sample collection
Colonoscopy
Undergo SOC colonoscopy
Nogapendekin Alfa
Given nogapendekin alfa inbakicept (N-803) SC
Placebo Administration
Given SC
Questionnaire Administration
Ancillary studies
Fox Chase Cancer Center, Philadelphia
Ohio State University Comprehensive Cancer Center, Columbus
Cleveland Clinic Foundation, Cleveland
University of Michigan Comprehensive Cancer Center, Ann Arbor
Mayo Clinic in Rochester, Rochester
Northwestern University, Chicago
University of Kansas Cancer Center, Kansas City
M D Anderson Cancer Center, Houston
Mayo Clinic Hospital in Arizona, Phoenix
University of Arizona Cancer Center - Prevention Research Clinic, Tucson
UCSF Medical Center-Parnassus, San Francisco
University of Colorado, Denver
Dana-Farber Cancer Institute, Boston
University of Puerto Rico, San Juan
National Cancer Institute (NCI)
NIH